Ethic Inc. Invests $234,000 in Align Technology, Inc. $ALGN

Ethic Inc. bought a new position in Align Technology, Inc. (NASDAQ:ALGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,240 shares of the medical equipment provider’s stock, valued at approximately $234,000.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Align Technology by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock worth $1,341,031,000 after purchasing an additional 185,187 shares during the last quarter. Ninety One UK Ltd grew its stake in shares of Align Technology by 58.7% in the first quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock worth $307,800,000 after purchasing an additional 716,954 shares during the last quarter. Invesco Ltd. grew its stake in shares of Align Technology by 12.7% in the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock worth $193,764,000 after purchasing an additional 137,553 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Align Technology by 32.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock worth $132,221,000 after purchasing an additional 202,616 shares during the last quarter. Finally, Navera Investment Management Ltd. grew its stake in shares of Align Technology by 3.0% in the second quarter. Navera Investment Management Ltd. now owns 787,559 shares of the medical equipment provider’s stock worth $149,126,000 after purchasing an additional 23,080 shares during the last quarter. 88.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on ALGN. Zacks Research raised Align Technology from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 30th. Evercore ISI raised their target price on Align Technology from $160.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday. Morgan Stanley raised their target price on Align Technology from $142.00 to $154.00 and gave the stock an “equal weight” rating in a research note on Thursday. Weiss Ratings cut Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, October 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Align Technology in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $174.36.

Align Technology Stock Performance

Align Technology stock opened at $138.43 on Friday. The stock’s 50 day simple moving average is $133.47 and its two-hundred day simple moving average is $162.00. The stock has a market cap of $10.03 billion, a price-to-earnings ratio of 26.83, a PEG ratio of 1.49 and a beta of 1.70. Align Technology, Inc. has a fifty-two week low of $122.00 and a fifty-two week high of $246.19.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.23. Align Technology had a return on equity of 14.06% and a net margin of 9.50%.The business had revenue of $995.69 million for the quarter, compared to analysts’ expectations of $980.75 million. During the same period in the previous year, the firm posted $2.35 EPS. The business’s revenue was up 1.8% on a year-over-year basis. Align Technology has set its Q4 2025 guidance at EPS. On average, analysts predict that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology declared that its board has initiated a stock buyback plan on Tuesday, August 5th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to purchase up to 2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.